Vincristine

This is a 3-years-old African American male, who presented to C.S. Mott Children's Hospital Hematology/Oncology unit today from the hematology clinic to continue Interim Maintenance #1 today for day 15 to receive Vincristine and high dose of methotrexate. He was accompanied by both parents. We obtained the history from M.C., his parents and previous hospital reports. His primary is Pre-B Cell Acute Lymphoblastic Leukemia in 5/25/2016 on AALL1131 high risk protocol. He generally has been doing well

with other treatments such as Rituximab, Radiation and Steroidal therapy. If chemotherapy does not decrease the rate of the cancer spreading, a bone marrow transplant or surgery will be done. Drugs such as Aoxprubican, Cytoxan, Methotrexate and Vincristine are prescribed. Certain chemotherapy drugs may be injected directly into the Cerebral Spinal Fluid. This method is known as Intrathecal

Neuroprotection is a term used to refer to strategies and relative mechanisms that shield the central nervous system (CNS) from neuronal injuries caused by chronic (e.g., Alzheimer’s and Parkinson’s diseases) or acute (e.g., stroke) neurodegenerative diseases (NDs) [1]. These acute or chronic diseases result from breakdown and deterioration of neurons of the CNS and often result to the deterioration of the cognitive as well as the intellectual faculties of the sufferers. The onset of NDs symptoms

72% and 76% 5-year survival rate of patients with estrogen ¬receptor ¬positive or progesterone ¬receptor ¬positive tumours has been reported for AC and AC followed by paclitaxel treatment, respectively13. The CAdo (carboplatin and etoposide, and vincristine, cyclophosphamide and doxorubicin) regimen is used to treat unrespectable and localised neuroblastoma in infants, with a 90% 5-year surivial rate13. While cyclophosphamide in conjunction with other chemotherapy treatment, surgery and radiation is

to more than 90% long-term survival.7 Cerebellar pilocytic astrocytomas are resectable and adjuvant therapy is not indicated. Those arising from the brainstem are often not completely resectable and require adjuvant chemotherapy (carboplatin and vincristine) and consideration of radiotherapy at progression. A clinical trial of BRAF and MAPK pathway inhibitors (AZD6244) is underway.8 A recent study has reported long-term follow up (mean of 18.4 years) for 101 children with benign posterior fossa astrocytomas

Chemotherapy: In the battle against cancer, Chemotherapy is one of the main technologies used for the treatment. Chemotherapy uses chemical to destroy cancer cells. Chemotherapy at times used in conjugation with surgery and radiation therapy to treat cancer. Chemotherapy is a very effective and widely used in therapeutics because it has the ability to treat metastatic cancer as well, that is in more than one location in your body. Chemotherapy will affect malignant cells in one of three ways:  Damage

and testicle relapse, radiation is sometimes used for resistance 14. Remission induction takes place almost immediately following the confirmation of the diagnosis and multiple drugs are administered at this time of induction including steroids vincristine

are used for cancer treatment but those are highly expensive due to less abundance of plants and very less amount of active constituent from plants like 500 mg vincristine from 5 kg vinca. So an indigenous drug, Sansevieria roxburghiana is selected for anti cancer activity as it is reported to have cytotoxicity in brine shrimp lethality assay18 and anti-cancer activity against Ehrlich ascites carcinoma in mice20

Diffuse large B cell lymphoma (DLBCL) is the most prevalent form of non-Hodgkin lymphomas (NHL) and constitutes 30-40% of NHL with a crude incidence of 3–4/100.000/year in the European Union [1]. Classification of DLBCL based on gene expression profiling (GEP) identifies three subgroups, namely germinal-centre B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, and primary mediastinal B-cell lymphoma (PMBCL) [3, 4]. DLBCL is a highly aggressive disease representing a clinically, morphologically

My Research Story: "So class I want you to write about what you want to be when you grow up," my teacher told us. I didn't know what I wanted to be yet, I would change my answer every time someone asked me that. I really thought about it this time. My favorite subject in school had always been science and I love learning about the human body and how different types of cells effect other cells. So I thought maybe I could be a cancer doctor. I already knew some stuff about cancer research before